FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg

FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet